Principal Financial Group’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,553
| Closed | -$584K | – | 2257 |
|
|
2025
Q2 | $584K | Sell |
4,553
-11,525
| -72% | -$1.2M | ﹤0.01% | 1973 |
|
|
2025
Q1 | $1.42M | Sell |
16,078
-105
| -0.6% | -$10.2K | ﹤0.01% | 1809 |
|
|
2024
Q4 | $1.41M | Buy |
16,183
+5,145
| +47% | +$471K | ﹤0.01% | 1833 |
|
|
2024
Q3 | $1.02M | Sell |
11,038
-47,153
| -81% | -$4.68M | ﹤0.01% | 1858 |
|
|
2024
Q2 | $6.27M | Sell |
58,191
-4,479
| -7% | -$448K | ﹤0.01% | 1482 |
|
|
2024
Q1 | $5.94M | Buy |
62,670
+48,160
| +332% | +$4.13M | ﹤0.01% | 1516 |
|
|
2023
Q4 | $1.34M | Buy |
14,510
+247
| +2% | +$16K | ﹤0.01% | 1808 |
|
|
2023
Q3 | $716K | Sell |
14,263
-473
| -3% | -$25.3K | ﹤0.01% | 1889 |
|
|
2023
Q2 | $931K | Sell |
14,736
-273
| -2% | -$14.8K | ﹤0.01% | 1855 |
|
|
2023
Q1 | $675K | Sell |
15,009
-990
| -6% | -$44.6K | ﹤0.01% | 1913 |
|
|
2022
Q4 | $701K | Buy |
15,999
+393
| +3% | +$18.8K | ﹤0.01% | 1908 |
|
|
2022
Q3 | $1.03M | Sell |
15,606
-426
| -3% | -$27.4K | ﹤0.01% | 1836 |
|
|
2022
Q2 | $809K | Sell |
16,032
-987
| -6% | -$57.8K | ﹤0.01% | 1962 |
|
|
2022
Q1 | $1.09M | Buy |
17,019
+339
| +2% | +$24.3K | ﹤0.01% | 1960 |
|
|
2021
Q4 | $1.79M | Sell |
16,680
-6,836
| -29% | -$715K | ﹤0.01% | 1867 |
|
|
2021
Q3 | $2.42M | Buy |
23,516
+748
| +3% | +$69.7K | ﹤0.01% | 1838 |
|
|
2021
Q2 | $2M | Sell |
22,768
-48,878
| -68% | -$4.48M | ﹤0.01% | 1909 |
|
|
2021
Q1 | $6.97M | Buy |
71,646
+46,079
| +180% | +$4.6M | ﹤0.01% | 1546 |
|
|
2020
Q4 | $2.87M | Buy |
25,567
+6,799
| +36% | +$717K | ﹤0.01% | 1721 |
|
|
2020
Q3 | $1.74M | Sell |
18,768
-854
| -4% | -$65.8K | ﹤0.01% | 1758 |
|
|
2020
Q2 | $1.53M | Buy |
19,622
+5,250
| +37% | +$355K | ﹤0.01% | 1745 |
|
|
2020
Q1 | $840K | Buy |
14,372
+773
| +6% | +$49.7K | ﹤0.01% | 1763 |
|
|
2019
Q4 | $1.09M | Sell |
13,599
-655
| -5% | -$49K | ﹤0.01% | 1816 |
|
|
2019
Q3 | $1.05M | Buy |
14,254
+1,369
| +11% | +$118K | ﹤0.01% | 1826 |
|
|
2019
Q2 | $1.22M | Buy |
12,885
+519
| +4% | +$42.8K | ﹤0.01% | 1815 |
|
|
2019
Q1 | $990K | Buy |
12,366
+588
| +5% | +$43.5K | ﹤0.01% | 1832 |
|
|
2018
Q4 | $635K | Sell |
11,778
-2,922
| -20% | -$178K | ﹤0.01% | 1874 |
|
|
2018
Q3 | $1.15M | Buy |
14,700
+2,076
| +16% | +$144K | ﹤0.01% | 1828 |
|
|
2018
Q2 | $801K | Sell |
12,624
-265
| -2% | -$21.1K | ﹤0.01% | 1881 |
|
|
2018
Q1 | $1.18M | Buy |
12,889
+437
| +4% | +$37.7K | ﹤0.01% | 1803 |
|
|
2017
Q4 | $939K | Buy |
12,452
+6,425
| +107% | +$452K | ﹤0.01% | 1852 |
|
|
2017
Q3 | $420K | Sell |
6,027
-1,081
| -15% | -$57.8K | ﹤0.01% | 1951 |
|
|
2017
Q2 | $360K | Buy |
+7,108
| New | +$302K | ﹤0.01% | 2012 |
|
Other funds holding BPMC
IA
HNB
Principal Financial Group's BPMC Position: Q3 2025 in Review
Principal Financial Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4,553 shares — an estimated $584K sold.
Principal Financial Group first reported a position in BPMC in Q2 2017 and held it in 33 quarters. The position peaked at $6.97M in Q1 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Principal Financial Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Principal Financial Group sold 4,553 Blueprint Medicines shares in Q3 2025, an estimated $584K.
- Principal Financial Group first reported a position in Blueprint Medicines in Q2 2017 and held it in 33 quarters.
- Principal Financial Group's Blueprint Medicines position peaked at $6.97M in Q1 2021.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Principal Financial Group's 13F filing for Q3 2025, filed 4 Nov 2025.